First-line medication: Clomiphene: Usually one to three tablets per day for five days from the 5th day of the menstrual cycle. The dose of the drug should be increased gradually from a small dose according to the response and effect under the guidance of the doctor. The ovulation rate in patients with polycystic ovaries can be more than 80% with clomiphene and the pregnancy rate can be 30-60% with clomiphene alone. The side effects of clomiphene are generally mild and include vasodilatory flushing (11%), ovarian enlargement (14%), abdominal discomfort (7.4%) and, rarely, blurred vision, nausea, vomiting, headache and fatigue, which may disappear within a few days to a few weeks after discontinuation and do not cause permanent damage. Ovarian hyperstimulation, ovarian enlargement, and even cyst formation may occur at high doses or in individual sensitive patients. For patients with well-developed follicles after clomiphene alone but unable to ovulate spontaneously, human chorionic gonadotropin (HCG) injections can be given at the appropriate time under medical supervision: for patients with low and thick cervical mucus or thin endometrium after clomiphene, estrogen supplementation can be given under medical supervision: for patients with combined insulin resistance and hyperandrogenemia, they also need to be given under medical supervision Drug pretreatment or combination of drugs to improve the ovulation promotion effect. Second-line treatment Letrozole: mainly used for patients with clomiphene resistance, applied on day 3-7 of menstruation, 2.5-7.5mg/d, after which the detection process is the same as clomiphene. Ovulation rate 80%. Minor side effects seen include gastrointestinal upset, fatigue, hot flashes, and head/back pain, but no clomiphene anti-cervical and endometrial estrogenic effects, and less ovarian hyperstimulation. It should be noted, however, that the current indication for this drug does not include “ovulatory treatment” and requires informed choice. Some hospitals still use HMG to promote ovulation: HMG is a gonadotropin extracted from the urine of postmenopausal women, containing both FSH and LH activity, and is not indicated for patients with elevated LH levels. It is also currently being phased out in the promotion of superovulation in women with normal LH levels. III. Superovulation promotion for assisted reproduction If the above two drugs are not successful in inducing ovulation after 6 consecutive cycles, and resistance is considered, it is necessary to resort to injectable ovulation promotion drugs or surgical treatment. For safety reasons, injectable ovulatory drugs, which mainly consist of follicle stimulating hormone (FSH) and luteinizing hormone (LH), should be used under the guidance and monitoring of a dedicated fertility doctor. So-called surgical treatment mainly refers to perforation of polycystic ovaries and is only used when medications are ineffective and for individual patients with high LH and free testosterone.